Hypomorphic Brca2 and Rad51c double mutant mice display Fanconi anemia, cancer and polygenic replication stress

被引:0
|
作者
Karl-Heinz Tomaszowski
Sunetra Roy
Carolina Guerrero
Poojan Shukla
Caezaan Keshvani
Yue Chen
Martina Ott
Xiaogang Wu
Jianhua Zhang
Courtney D. DiNardo
Detlev Schindler
Katharina Schlacher
机构
[1] The University of Texas MD Anderson Cancer Center,Department of Cancer Biology
[2] The University of Texas MD Anderson Cancer Center,Department of Neurosurgery
[3] The University of Texas MD Anderson Cancer Center,Department of Genomic Medicine
[4] The University of Texas MD Anderson Cancer Center,Department of Leukemia
[5] University of Wuerzburg,Institut fuer Humangenetik
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The prototypic cancer-predisposition disease Fanconi Anemia (FA) is identified by biallelic mutations in any one of twenty-three FANC genes. Puzzlingly, inactivation of one Fanc gene alone in mice fails to faithfully model the pleiotropic human disease without additional external stress. Here we find that FA patients frequently display FANC co-mutations. Combining exemplary homozygous hypomorphic Brca2/Fancd1 and Rad51c/Fanco mutations in mice phenocopies human FA with bone marrow failure, rapid death by cancer, cellular cancer-drug hypersensitivity and severe replication instability. These grave phenotypes contrast the unremarkable phenotypes seen in mice with single gene-function inactivation, revealing an unexpected synergism between Fanc mutations. Beyond FA, breast cancer-genome analysis confirms that polygenic FANC tumor-mutations correlate with lower survival, expanding our understanding of FANC genes beyond an epistatic FA-pathway. Collectively, the data establish a polygenic replication stress concept as a testable principle, whereby co-occurrence of a distinct second gene mutation amplifies and drives endogenous replication stress, genome instability and disease.
引用
收藏
相关论文
共 41 条
  • [31] Distinct roles of FANCO/RAD51C protein in DNA damage signaling and repair: Implications for Fanconi anemia and breast cancer susceptibility (vol 287, pg 3366, 2012)
    Somyajit, Kumar
    Subramanya, Shreelakshmi
    Nagaraju, Ganesh
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (35) : 13198 - 13198
  • [32] Germline Mutations in PALB2, BRCA1, and RAD51C, Which Regulate DNA Recombination Repair, in Patients With Gastric Cancer
    Sahasrabudhe, Ruta
    Lott, Paul
    Bohorquez, Mabel
    Toal, Ted
    Estrada, Ana P.
    Suarez, John J.
    Brea-Fernandez, Alejandro
    Cameselle-Teijeiro, Jose
    Pinto, Carla
    Ramos, Irma
    Mantilla, Alejandra
    Prieto, Rodrigo
    Corvalan, Alejandro
    Norero, Enrique
    Alvarez, Carolina
    Tapia, Teresa
    Carvallo, Pilar
    Gonzalez, Luz M.
    Cock-Rada, Alicia
    Solano, Angela
    Neffa, Florencia
    Della Valle, Adriana
    Yau, Chris
    Soares, Gabriela
    Borowsky, Alexander
    Hu, Nan
    He, Li-Ji
    Han, Xiao-You
    Taylor, Philip R.
    Goldstein, Alisa M.
    Torres, Javier
    Echeverry, Magdalena
    Ruiz-Ponte, Clara
    Teixeira, Manuel R.
    Carvajal-Carmona, Luis G.
    GASTROENTEROLOGY, 2017, 152 (05) : 983 - +
  • [33] Germline testing of BRCA1, BRCA2, PALB2 and CHEK2 c.1100delC in 1514 triple negative familial and isolated breast cancers from a single centre, with extended testing of ATM, RAD51C and RAD51D in over 400
    Woodward, Emma R.
    Lalloo, Fiona
    Forde, Claire
    Pugh, Sarah
    Burghel, George J.
    Schlecht, Helene
    Harkness, Elaine F.
    Howell, Anthony
    Howell, Sacha J.
    Gandhi, Ashu
    Evans, D. Gareth
    JOURNAL OF MEDICAL GENETICS, 2024, 61 (04) : 385 - 391
  • [34] Analysis of germ-line mutations in non-syndromic malignancies with concurrent pathogenic variants in BRCA1, BRCA2, PALB2, ATM, CHEK2, and RAD51C/D
    Miller, E. M.
    Mullins, J.
    Jain, A.
    Chaudhry, A.
    Mi, D.
    Usman, R.
    Jones, T.
    Baca, Y.
    Xiu, J.
    Korn, W. M.
    Cummings, S.
    Vidal, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1229 - S1229
  • [35] A functional assay for the identification of DNA double-strand break repair deficiency in heterozygous carriers of BRCA1/2 and RAD51C mutations.
    Becker, A.
    Graeser, M.
    Landwehr, C.
    Hilger, T.
    Baus, W.
    Weber, R.
    Wappenschmidt, B.
    Schmutzler, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Brca2 C-terminus interacts with Rad51 and contributes to nuclear focus formation in double-strand break repair of DNA
    Ochiai, Kazuhiko
    Morimatsu, Masami
    Yoshikawa, Yasunaga
    Syuto, Bunei
    Hashizume, Kazuyoshi
    BIOMEDICAL RESEARCH-TOKYO, 2004, 25 (06): : 269 - 275
  • [37] Mutation status of RAD51C, PALB2, and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1/2 mutation
    Katsutoshi, Sato
    Nomura, Sachio
    Iwase, Takuji
    Yoshida, Reiko
    Miki, Yoshio
    Arai, Masami
    CANCER SCIENCE, 2018, 109 : 998 - 998
  • [38] SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA trial
    Balmana, J.
    Pascual, T.
    Llop-Guevara, A.
    Tolosa, P.
    Blancas Lopez-Barajas, I.
    Perez Lopez, M. E.
    Adamo, B.
    Teruel-Garcia, I.
    Ponce, J.
    Gonzalez-Cordero, M.
    Vinas Villaro, G.
    Lema Roso, L.
    Salvador Bofill, F. J.
    Martinez, M. T. M.
    Guerrero, A. N. E.
    Prat, A.
    Serra Elizalde, V.
    ANNALS OF ONCOLOGY, 2022, 33 : S146 - S147
  • [39] RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers:: Results from a combined analysis of 19 studies
    Antoniou, Antonis C.
    Sinilnikova, Olga M.
    Simard, Jacques
    Leone, Melanie
    Dumont, Martine
    Neuhausen, Susan L.
    Struewing, Jeffery P.
    Stoppa-Lyonnet, Dominique
    Barjhoux, Laure
    Hughes, David J.
    Coupier, Isabelle
    Belotti, Muriel
    Lasset, Christine
    Rebbeck, Timothy R.
    Wagner, Theresa
    Lynch, Henry T.
    Domchek, Susan M.
    Nathanson, Katherine L.
    Garber, Judy E.
    Weitzel, Jeffrey
    Narod, Steven A.
    Tomlinson, Gail
    Olopade, Olufunmilayo I.
    Godwin, Andrew
    Isaacs, Claudine
    Jakubowska, Anna
    Lubinski, Jan
    Gronwald, Jacek
    Gorski, Bohdan
    Byrski, Tomasz
    Huzarski, Tomasz
    Peock, Susan
    Cook, Margaret
    Baynes, Caroline
    Murray, Alexandra
    Rogers, Mark
    Daly, Peter A.
    Dorkins, Huw
    Schmutzler, Rita K.
    Versmold, Beatrix
    Engel, Christoph
    Meindl, Alfons
    Arnold, Norbert
    Niederacher, Dieter
    Deissler, Helmut
    Spurdle, Amanda B.
    Chen, Xiaoqing
    Waddell, Nicola
    Cloonan, Nicole
    Kirchhoff, Tomas
    AMERICAN JOURNAL OF HUMAN GENETICS, 2007, 81 (06) : 1186 - 1200
  • [40] SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA TRIAL
    Balmana, Judith
    Pascual, Tomas
    Llop-Guevara, Alba
    Tolosa, Pablo
    Blancas, Isabel
    Perez-Lopez, Maria-Eva
    Adamo, Barbara
    Teruel, Iris
    Ponce, Jose
    Gonzalez, Marta
    Vinas, Gemma
    Lema, Laura
    Salvador, Francisco Javier
    Martinez, Ma Teresa
    Espinosa, Alejandra
    Prat, Aleix
    Serra, Violeta
    CANCER RESEARCH, 2023, 83 (05)